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Arginine deprivation causes death of up to 80% of cancer cell lines in vitro, but in the body, citrulline would be available as a
convertible source of this amino acid in vivo. Some tumour cell lines, notably the vast majority of melanomas and hepatocellular
carcinomas, tend to be deficient in argininosuccinate synthetase (EC 6.5.4.3.), and therefore cannot recycle citrulline to arginine.
Argininosuccinate synthetase is present at levels that convert enough citrulline to arginine to allow limited growth in about half of a
modest range of malignant cell types analysed in this study. Attempts to rescue cells that are unable to utilise citrulline with the
immediate downstream product, argininosuccinate, had very limited success in a few tumour cell lines. Particularly noteworthy is the
demonstration that argininosuccinate was totally incapable of rescuing cells that utilise citrulline efficiently, consistent with tight
channelling (coupling) of argininosuccinate synthetase and argininosuccinate lyase in the urea cycle. The findings suggest that an
excellent opportunity exists for further exploitation of arginine deprivation in the selective killing of tumour cells.
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Arginine is a vital amino acid for many metabolic processes other
than protein synthesis (e.g. creatine production, polyamine
synthesis and nitric oxide (NO) generation). Its removal from
culture medium by medium formulation or arginase treatment
quickly leads to death in B80% of tumour cell lines (Scott et al,
2000). The addition of citrulline can often circumvent this
deficiency, but few cells are capable of its biosynthesis in culture.
Arginine deficiency in vivo has been induced by various means,
but is less effectively achieved because body homeostasis is too
robust, and citrulline generation is difficult to control. Having
successfully reduced L1210 cells in culture to negligible viability in
3–5 days with arginase (EC 3.5.3.1), citrulline supplementation in
the continued presence of the enzyme partially circumvented the
arginine deficiency. The rate of conversion became a rate-limiting
factor, most noticeably in such fast-growing leukaemia as L1210
(Philip et al, 2003). In a corresponding in vivo study, arginase
treatment of DBA/2 mice injected intraperitoneally with 1210 cells
increased neither their survival time nor decreased tumour
burden, despite plasma arginine falling to B1–2mM level. Plasma
citrulline remained normal, and therefore the tumour cells must
have converted citrulline to arginine fast enough to sustain
relatively normal tumour growth rate (Wu and Morris, 1998; Philip
et al, 2003). This makes it difficult to understand how previous
in vivo work with arginase and arginine deiminase could have
achieved significant inhibition of tumour growth under similar
conditions (Bach and Swaine, 1965; Miyazaki et al, 1990), and begs
further analysis of the ability of tumour cells to use citrulline
in lieu of arginine (Wheatley and Campbell, 2002). Sugimura et al
(1992) found that four out of five human melanoma cell lines
deprived of arginine with arginine deiminase (EC 3.5.3.6) could
not be rescued with citrulline, but grew when argininosuccinate,
the immediate downstream intermediate, was supplied. Another
tumour type that is characteristically deficient in this enzyme is
human hepatocellular carcinoma (Ensor et al, 2002). With regard
to melanomas, however, we found that B16F10, a murine
melanoma cell line, was not deficient in argininosuccinate
synthetase, and therefore an inability to handle citrulline is not
an idiosyncratic feature of melanomas, at least not in the mouse.
Since B16F10 cells grew well on citrulline with little curtailment of
its kinetics, we carefully selected a small panel of other tumour and
transformed cell lines, mostly of human origin, for a preliminary
in vitro analysis, which included several examples of melanomas,
leukaemias and osteosarcomas. The primary aim was to establish
the degree of variability in the metabolism of citrulline in cultured
cells before embarking on the more difficult and extensive task of
analysing tumour biopsies and primary cultures grown from them.
MATERIALS AND METHODS
Cell culture
Cells from a wide range of suppliers and sources were grown in
RPMI 1640 medium (Life Technologies, Paisley, UK) at 371Ci na
humidified atmosphere of 5% CO2. Cell counting involved a
Coulter electronic particle counter (Model ZM; Coulter Electronics,
Luton). Counts are representative of the normal cell population,
within standard parameters, and unless otherwise stated cannot be
taken as an indication of viability. All cell cultures were routinely
screened, and just prior to experimental use, for four types
of mycoplasma, using the Mycoplasma Screening Kit of
Roche (Mannheim, Germany), according to the manufacturer’s Received 31 January 2003; revised 16 May 2003; accepted 22 May 2003
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tested positive.
Experimental design
Cells were seeded at approximately 50000 cells per well in 12-well
plates and allowed to settle in RPMI medium containing 1mM
arginine and 5% dialysed foetal calf serum (FCS) overnight. Prior
to treatment, cells were washed with prewarmed arginine-free
medium (hereafter AFM) and treated with fresh AFM to which
arginine, argininosuccinate, citrulline and ornithine was added at
1m M, where appropriate. Native bovine arginase (Sigma, Poole,
UK) or human recombinant arginase (Kyoto, Japan) was added at
a concentration of 1Uml
 1 to arginine-containing RPMI. In the
case of L1210 cells, a suspension culture line, cells were treated
immediately on being resuspended at the desired concentration in
AFM to which arginine, argininosuccinate, citrulline and ornithine
were added as desired.
Enzyme activity
Arginase was analysed in vitro overtime at 371C in a humidified
atmosphere of 5% CO2 to show that it maintained activity over the
course of each experiment, using the ornithine method of Ochoa
et al (2000). The specific activity of arginase was given as the
amount of ornithine produced in mmolmin
 1mg protein
 1. In all,
1U of arginase was taken as the amount that broke down
1mmolargininemin
 1.
RESULTS AND DISCUSSION
Cell differences in citrulline and argininosuccinate
utilisation
Melanomas Table 1 is a compilation of our findings on 11
malignant or transformed cell lines and one normal control
(human diploid fibroblasts, designated JMF9). Fibroblasts have
the ability to use citrulline, and their behaviour is consistent
with tight coupling of the citrulline-arginine pathway (Cheung
et al, 1989; Schimke, 1964) because of their complete inability to
handle argininosuccinate in the absence of citrulline. The
melanoma data in Table 1 are in accord with Sugimura et al
(1992) findings in melanomas; our data confirm that two of them
were unable to metabolise citrulline (A375 and MEWO), but that
they could grow in argininosuccinate-supplemented medium. The
third melanoma line, G361, could survive in citrulline but showed
little or no real growth, indicating a very low maintenance level of
argininosuccinate synthetase. It therefore has almost total
dependence on arginine, also in accord with the data of Sugimura
et al (1992).
The findings on human melanomas contrast sharply with those
on mouse B16F10 melanoma cells, which efficiently handle
citrulline (Table 1), but unlike A375 and MEWO, showed no signs
of being rescued by argininosuccinate. Therefore, clear distinctions
exist between melanoma cell lines in their ability to handle
citrulline and argininosuccinate.
Ensor et al (2002) found a complete absence of argininosucci-
nate synthetase in both human melanoma and hepatocellular
carcinoma cell lines. The fact that close to half of all tumour cell
types given in Table 1 failed to convert citrulline seems a high
percentage to us, even when we know that these other investigators
confined themselves to melanomas and hepatocellular carcinomas
(Sugimura et al, 1992; Ensor et al, 2002). However, the latter
authors do concede that several different tumour cells types are
not inhibited so strongly by arginine deprivation and can use
citrulline, although they furnished no actual data on them other
than their designations.
Other tumour types With regard to osteosarcoma, SAos-2
behaved in the same manner as G361, which is Type A. Another
osteosarcoma, SAos-2, behaved in a similar manner to MEWO in
utilising argininosuccinate, but not citrulline, and is therefore Type
B. This again is consistent with tight metabolic channelling,
excluding argininosuccinate from the pathway when it is fully
intact, and ensuring that only endogenous argininosuccinate (that
generated in situ from citrulline) is used by the lyase to form
arginine. The three human leukaemic cell lines (L1210, Jurkat and
HL428, see Table 1) had normal phenotypes with regard to
arginine and citrulline metabolism. Although Sugimura et al
(1990) showed that some leukaemic cell lines may overexpress
argininosuccinate synthetase, we found no evidence that citrulline
was the preferred substrate. Less is known about leukaemic
cultures with respect to the relevant enzymes of the urea cycle, and
clearly a more extensive series of analyses is required before we
can establish whether the relationship with mRNA copy number
per cell for argininosuccinate synthetase holds fast (work in
progress) as in melanomas and hepatocellular carcinomas.
However, the point to be emphasised is that leukaemias are
diametrically opposite to (human) melanoma or hepatocellular
carcinomas with regard to arginine-citrulline metabolism.
Table 1 Summary of the ability of a range of human and murine normal and malignant cell lines to utilise citrulline, argininosuccinate and arginine
Type C
Cell designation Species Origin Type A
a Type B AS+ AS 
JMF9 Human Skin fibroblast +
A375 Human Melanoma +
MEWO Human Melanoma +
G361 Human Melanoma +
B16F10
b Murine Melanoma +
HL428 Human Leukaemia +
JURKAT Human Leukaemia +
L1210 Murine Leukaemia +
HeLa Human Cervical carcinoma +
SAos-2 Human Osteogenic sarcoma +
CHO Chinese hamster Ovary +
aThis refers to the absence of growth when twice the concentration of citrulline was added instead of arginine.
bNon-human lines shaded. Type A: grow only when arginine is
present; Type B: grow on arginine or argininosuccinate, but not citrulline; Type C/As+: grow on citrulline and argininosuccinate; Type C/As : grow on citrulline, but cannot grow
on argininosuccinate.
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how argininosuccinate was prepared, the product could have free
arginine as a contaminant. This possibility was eliminated by
HPLC analysis of the product, which gave no significant arginine
peak. Breakdown soon after the preparation of argininosuccinate
medium did not show any released (free) arginine. Although
rescue with argininsuccinate in AFM with traces of contaminating
arginine is therefore very unlikely, it would have been pre-
emptorily destroyed before the cells could make use of it where
arginase had been used to create the deficiency (see Figure 1 a–j).
CONCLUDING REMARKS
The small sample of cell lines examined in our study shows that
half are deficient in argininosuccinate synthetase, with melanomas
being well represented. The data on argininosuccinate usage in
relation to citrulline convincingly illustrate that a tightly coupled
pathway (or channel) normally operates, thereby preventing the
access of argininosuccinate to argininosuccinate lyase (EC 4.3.2.1.),
which would explain the absence of Type C/AS
þ tumours
(Table 1). This pathway seems to be disrupted, or at least much
less tight, in other cell lines of malignant and transformed
phenotypes, but so far has not applied to any of the leukaemic
lines analysed.
Rescue of cell lines incapable of utilising citrulline with
argininosuccinate does occur, but with considerable differences
between the cell lines. CHO is an excellent example of a cell line
that cannot use it and is therefore totally dependent on arginine.
This is more noteworthy because the generalisation of Eagle (1959)
based on a couple of transformed lines (mouse L strain cells) and
malignant lines (HeLa and KB) that citrulline can substitute for
arginine is frankly not true across the board (cf also Schimke,
1964). However, MEWO can use argininosuccinate, and A375 cells
grow well on it, whereas G361 survive although they do not
proliferate to any significant extent in its presence. We should also
note that normal fibroblasts manage well on citrulline, but do not
thrive in the presence of argininosuccinate (Table 1; Philip et al,
2003). However, until more extensive studies are carried out we
will not know whether most normal cell cultures can convert
citrulline to arginine. Conversely, more extensive investigations of
tumour lines may show just how capable they are, in general, in
utilising citrulline (work in progress). The idea that virtually all
human melanomas and hepatocellular carcinomas have a similar
phenotypic defect with regard to argininosuccinate synthetase is
inconsistent with the heterogeneous origins of tumours. Also,
this is not true of the mouse melanoma, and leukaemias show
the opposite.
Nevertheless, the inability of a number of tumour cell lines to
utilise citrulline renders them prime targets for eradication by
arginine deprivation, whether achieved by leaving it out in
medium formulation or using catabolic enzymes in its presence.
This potential Achilles’ heel in tumour metabolism deserves
further exploitation in view of our previous findings (Scott et al,
2000; Wheatley and Campbell, 2001, 2002; Philip et al, 2003).
Although melanomas do not exclusively show this argininosucci-
nate synthetase deficiency, the findings show that most cases of
this dangerous and aggressive tumour can be appropriately and
quickly selected for treatment. They are the preferred targets for
therapy, for which screening of primary tumours has already
begun.
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Figure 1 The left-hand side of each pair is made arginine-deficient in
RPMI 1640 during preparation and has a 5% dialysed serum supplement.
The right-hand side of each pair refers to cultures in complete RPMI 1640
with 5% dialysed serum, but to which was added 1Uml
 1 human
recombinant arginase. The symbols are the same throughout: &,n o
supplementation (arginine deficient control); ’, arginine (1mM); J,
citrulline (1mM); K, argininosuccinate (1mM); n, ornithine (1mM; Figure 1
only). The points are means of three determinations, with the bars (often
hidden within the symbols) giving 1s.d. of the mean. Each cell line was the
subject of more than two experiments from which these data were
graphed, and most have been examined many more times since these data
were first compiled, with similar results. (A, B) A375; (C, D) CHO; (E, F)
B16F10; (G, H) MEWO; (I, J) L1210.
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